Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.04
NYSE:MNK's Cash-to-Debt is ranked lower than
97% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. NYSE:MNK: 0.04 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:MNK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.08 Max: 0.31
Current: 0.04
0.04
0.31
Equity-to-Asset 0.43
NYSE:MNK's Equity-to-Asset is ranked lower than
77% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NYSE:MNK: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:MNK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.35 Max: 0.43
Current: 0.43
0.25
0.43
Debt-to-Equity 0.98
NYSE:MNK's Debt-to-Equity is ranked lower than
84% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. NYSE:MNK: 0.98 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:MNK' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.7  Med: 1.14 Max: 1.67
Current: 0.98
0.7
1.67
Debt-to-EBITDA 6.10
NYSE:MNK's Debt-to-EBITDA is ranked lower than
83% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. NYSE:MNK: 6.10 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:MNK' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 4.16  Med: 5.44 Max: 12.03
Current: 6.1
4.16
12.03
Interest Coverage 1.05
NYSE:MNK's Interest Coverage is ranked lower than
96% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. NYSE:MNK: 1.05 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:MNK' s Interest Coverage Range Over the Past 10 Years
Min: 1.05  Med: 1.74 Max: 538
Current: 1.05
1.05
538
Piotroski F-Score: 5
Altman Z-Score: 0.73
Beneish M-Score: -2.42
WACC vs ROIC
67.99%
-41.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 13.86
NYSE:MNK's Operating Margin % is ranked higher than
70% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. NYSE:MNK: 13.86 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:MNK' s Operating Margin % Range Over the Past 10 Years
Min: 8.07  Med: 13.08 Max: 19.74
Current: 13.86
8.07
19.74
Net Margin % 59.85
NYSE:MNK's Net Margin % is ranked higher than
98% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. NYSE:MNK: 59.85 )
Ranked among companies with meaningful Net Margin % only.
NYSE:MNK' s Net Margin % Range Over the Past 10 Years
Min: -19.35  Med: 7.45 Max: 66.25
Current: 59.85
-19.35
66.25
ROE % 28.15
NYSE:MNK's ROE % is ranked higher than
92% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. NYSE:MNK: 28.15 )
Ranked among companies with meaningful ROE % only.
NYSE:MNK' s ROE % Range Over the Past 10 Years
Min: -10.28  Med: 9.37 Max: 36.2
Current: 28.15
-10.28
36.2
ROA % 11.12
NYSE:MNK's ROA % is ranked higher than
83% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. NYSE:MNK: 11.12 )
Ranked among companies with meaningful ROA % only.
NYSE:MNK' s ROA % Range Over the Past 10 Years
Min: -3.91  Med: 3.31 Max: 13.87
Current: 11.12
-3.91
13.87
ROC (Joel Greenblatt) % 19.96
NYSE:MNK's ROC (Joel Greenblatt) % is ranked higher than
65% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. NYSE:MNK: 19.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:MNK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.34  Med: 26.56 Max: 50.3
Current: 19.96
3.34
50.3
3-Year Revenue Growth Rate 9.00
NYSE:MNK's 3-Year Revenue Growth Rate is ranked higher than
62% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. NYSE:MNK: 9.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:MNK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -11.2  Med: -4.65 Max: 9
Current: 9
-11.2
9
3-Year EBITDA Growth Rate 36.40
NYSE:MNK's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. NYSE:MNK: 36.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:MNK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.5  Med: 23.95 Max: 51.9
Current: 36.4
-7.5
51.9
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:MNK's 30-Y Financials

Financials (Next Earnings Date: 2018-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

MNK Guru Trades in Q3 2017

Arnold Schneider 159,400 sh (New)
HOTCHKIS & WILEY 969,640 sh (+21.20%)
Mario Gabelli 29,425 sh (unchged)
First Eagle Investment 187 sh (unchged)
David Dreman 84 sh (unchged)
John Paulson 6,626,672 sh (-3.84%)
Steven Cohen 584,700 sh (-33.16%)
» More
Q4 2017

MNK Guru Trades in Q4 2017

Pioneer Investments 8,427 sh (New)
Jim Simons 444,302 sh (New)
Paul Tudor Jones 49,608 sh (New)
Chuck Royce 405,000 sh (New)
Arnold Schneider 824,414 sh (+417.20%)
HOTCHKIS & WILEY 2,044,840 sh (+110.89%)
First Eagle Investment 187 sh (unchged)
David Dreman 84 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli Sold Out
John Paulson 3,670,992 sh (-44.60%)
» More
Q1 2018

MNK Guru Trades in Q1 2018

Steven Cohen 742,200 sh (New)
Chuck Royce 1,186,701 sh (+193.01%)
Pioneer Investments 22,016 sh (+161.26%)
Arnold Schneider 1,253,263 sh (+52.02%)
HOTCHKIS & WILEY 2,701,540 sh (+32.11%)
John Paulson 3,670,992 sh (unchged)
Steven Cohen 700,000 sh (unchged)
David Dreman 84 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
First Eagle Investment Sold Out
» More
Q2 2018

MNK Guru Trades in Q2 2018

Joel Greenblatt 27,337 sh (New)
Chuck Royce 1,364,301 sh (+14.97%)
Arnold Schneider 1,257,463 sh (+0.34%)
Steven Cohen 350,000 sh (unchged)
John Paulson 3,670,992 sh (unchged)
Steven Cohen Sold Out
HOTCHKIS & WILEY 2,606,240 sh (-3.53%)
Pioneer Investments 11,441 sh (-48.03%)
» More
» Details

Insider Trades

Latest Guru Trades with MNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
HOTCHKIS & WILEY 2018-06-30 Reduce -3.53%0.01%$11.99 - $20.19 $ 27.4873%2,606,240
Arnold Schneider 2018-06-30 Add 0.34%0.02%$11.99 - $20.19 $ 27.4873%1,257,463
Joel Greenblatt 2018-06-30 New Buy0.01%$11.99 - $20.19 $ 27.4873%27,337
HOTCHKIS & WILEY 2018-03-31 Add 32.11%0.04%$13.88 - $23.52 $ 27.4852%2,701,540
Arnold Schneider 2018-03-31 Add 52.02%1.42%$13.88 - $23.52 $ 27.4852%1,253,263
First Eagle Investment 2018-03-31 Sold Out $13.88 - $23.52 $ 27.4852%0
John Paulson 2017-12-31 Reduce -44.60%2%$19.98 - $38.87 $ 27.482%3,670,992
HOTCHKIS & WILEY 2017-12-31 Add 110.89%0.09%$19.98 - $38.87 $ 27.482%2,044,840
Arnold Schneider 2017-12-31 Add 417.20%3.29%$19.98 - $38.87 $ 27.482%824,414
Mario Gabelli 2017-12-31 Sold Out 0.01%$19.98 - $38.87 $ 27.482%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:SHSE:600993, HKSE:02877, TSE:4547, TPE:6452, SHSE:603456, SZSE:002550, SZSE:300110, SHSE:600557, ROCO:6446, BOM:524494, SZSE:002435, XBRU:FAGR, NAS:MNTA, SHSE:600750, TPE:1707, SHSE:600812, HKSE:01558, NAS:ENDP, SZSE:300725, NAS:PCRX » details
Traded in other countries:MCD.Germany,
Headquarter Location:UK
Mallinckrodt PLC is a drug manufacturing company that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products. It operates in two segments including branded pharmaceuticals and generic drugs.

Mallinckrodt is a specialty pharmaceutical company that was spun off from Covidien. The company has two segments in branded pharmaceuticals and generic drugs following the sale of its nuclear imaging business in 2016. Branded drugs make up approximately 70% of revenue. The firm's generic drug segment focuses primarily on products in the pain therapeutic area.

Top Ranked Articles about Mallinckrodt PLC

Mallinckrodt To Present At Jefferies London Healthcare Conference
Mallinckrodt's Stratatech Company Awarded $26 Million in Additional BARDA Funding for Pediatric Studies of StrataGraft® Skin Tissue in Thermal Burns
U.S. FDA Announces Joint Advisory Committee Review of Mallinckrodt's Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride)
Dance Biopharm Holdings announces the appointment of Anne Whitaker as Chief Executive Officer
Mallinckrodt plc To Report Earnings Results For Third Quarter Of Fiscal 2018
Mallinckrodt To Present At Cantor Global Healthcare Conference
The Mallinckrodt Rejection Is Not Surprising The drugmaker recently received a rejection from the FDA
I recently predicted that Mallinckrodt PLC’s (NYSE:MNK) new drug application for stannsoporfin would be rejected. Low and behold, on Wednesday, the company confirmed that the Food and Drug Administration had rejected the treatment. After making such predictions, I’m often asked how I am so accurate.  Read more...
Mallinckrodt And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of Inhaled Xenon Gas Therapy
Mallinckrodt Confirms Receipt of Stannsoporfin Complete Response Letter
New Mallinckrodt Data Analysis Shows Limited Use Of Opioid-Free Analgesia, Underutilization In Some Patients More Prone To Opioid-Related Adverse Events

Ratios

vs
industry
vs
history
PE Ratio 1.62
MNK's PE Ratio is ranked higher than
98% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.77 vs. MNK: 1.62 )
Ranked among companies with meaningful PE Ratio only.
MNK' s PE Ratio Range Over the Past 10 Years
Min: 0.68  Med: 14.96 Max: 73.31
Current: 1.62
0.68
73.31
Forward PE Ratio 3.79
MNK's Forward PE Ratio is ranked higher than
99% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.60 vs. MNK: 3.79 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 1.69
MNK's PE Ratio without NRI is ranked higher than
99% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.20 vs. MNK: 1.69 )
Ranked among companies with meaningful PE Ratio without NRI only.
MNK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.69  Med: 33.14 Max: 3311.75
Current: 1.69
0.69
3311.75
PB Ratio 0.36
MNK's PB Ratio is ranked higher than
98% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. MNK: 0.36 )
Ranked among companies with meaningful PB Ratio only.
MNK' s PB Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.45 Max: 3.59
Current: 0.36
0.16
3.59
PS Ratio 0.86
MNK's PS Ratio is ranked higher than
84% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MNK: 0.86 )
Ranked among companies with meaningful PS Ratio only.
MNK' s PS Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.09 Max: 6.35
Current: 0.86
0.38
6.35
Price-to-Operating-Cash-Flow 3.23
MNK's Price-to-Operating-Cash-Flow is ranked higher than
96% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. MNK: 3.23 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MNK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.36  Med: 7.56 Max: 40.56
Current: 3.23
1.36
40.56
EV-to-EBIT 34.57
MNK's EV-to-EBIT is ranked lower than
80% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. MNK: 34.57 )
Ranked among companies with meaningful EV-to-EBIT only.
MNK' s EV-to-EBIT Range Over the Past 10 Years
Min: 16.1  Med: 43.1 Max: 231
Current: 34.57
16.1
231
EV-to-EBITDA 8.05
MNK's EV-to-EBITDA is ranked higher than
82% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. MNK: 8.05 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 11.5 Max: 34.2
Current: 8.05
5.6
34.2
EV-to-Revenue 2.98
MNK's EV-to-Revenue is ranked higher than
52% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. MNK: 2.98 )
Ranked among companies with meaningful EV-to-Revenue only.
MNK' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.5  Med: 3.45 Max: 8.9
Current: 2.98
1.5
8.9
PEG Ratio 0.07
MNK's PEG Ratio is ranked higher than
99% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. MNK: 0.07 )
Ranked among companies with meaningful PEG Ratio only.
MNK' s PEG Ratio Range Over the Past 10 Years
Min: 0.03  Med: 0.04 Max: 0.08
Current: 0.07
0.03
0.08
Current Ratio 2.27
MNK's Current Ratio is ranked lower than
53% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. MNK: 2.27 )
Ranked among companies with meaningful Current Ratio only.
MNK' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 2.1 Max: 2.86
Current: 2.27
1.06
2.86
Quick Ratio 2.06
MNK's Quick Ratio is ranked higher than
54% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. MNK: 2.06 )
Ranked among companies with meaningful Quick Ratio only.
MNK' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 1.64 Max: 2.41
Current: 2.06
0.81
2.41
Days Inventory 75.33
MNK's Days Inventory is ranked higher than
72% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. MNK: 75.33 )
Ranked among companies with meaningful Days Inventory only.
MNK' s Days Inventory Range Over the Past 10 Years
Min: 71.49  Med: 79.8 Max: 169.11
Current: 75.33
71.49
169.11
Days Sales Outstanding 44.16
MNK's Days Sales Outstanding is ranked higher than
81% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. MNK: 44.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.16  Med: 61.14 Max: 105.41
Current: 44.16
44.16
105.41
Days Payable 20.12
MNK's Days Payable is ranked lower than
91% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. MNK: 20.12 )
Ranked among companies with meaningful Days Payable only.
MNK' s Days Payable Range Over the Past 10 Years
Min: 20.12  Med: 32.79 Max: 52.77
Current: 20.12
20.12
52.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 9.40
MNK's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. MNK: 9.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.3  Med: -24.55 Max: 9.4
Current: 9.4
-26.3
9.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 5.18
MNK's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
85% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. MNK: 5.18 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MNK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.63  Med: 3.51 Max: 13.05
Current: 5.18
1.63
13.05
Price-to-Median-PS-Value 0.42
MNK's Price-to-Median-PS-Value is ranked higher than
86% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. MNK: 0.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MNK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 1.02 Max: 2.82
Current: 0.42
0.22
2.82
Price-to-Peter-Lynch-Fair-Value 0.07
MNK's Price-to-Peter-Lynch-Fair-Value is ranked higher than
99% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.41 vs. MNK: 0.07 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
MNK' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.03  Med: 0.05 Max: 0.07
Current: 0.07
0.03
0.07
Earnings Yield (Greenblatt) % 2.93
MNK's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. MNK: 2.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MNK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 2.3 Max: 6.2
Current: 2.93
0.4
6.2
Forward Rate of Return (Yacktman) % -7.70
MNK's Forward Rate of Return (Yacktman) % is ranked lower than
79% of the 421 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.96 vs. MNK: -7.70 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MNK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -46.3  Med: -15.8 Max: -1.2
Current: -7.7
-46.3
-1.2

More Statistics

Revenue (TTM) (Mil) $2,790.50
EPS (TTM) $ 17.17
Beta1.15
Volatility81.07%
52-Week Range $11.65 - 36.65
Shares Outstanding (Mil)83.21

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 2,490 2,513 2,540 2,292
EBIT (Mil $) 234 375
EBITDA (Mil $) 1,014 1,156
EPS ($) 0.32 1.09 7.94 6.59
EPS without NRI ($) 0.32 1.09 7.94 6.59
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-14.34%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}